Arca
Skip to content
Tools
Tools

Candidemia

Drug research and approvals for candidemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 3 studies of candidemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 2 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 3
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 3 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 6

How its trials ended

62 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 20 whose ending is known, 55% met their primary endpoint, 10% missed it and 35% stopped early.

  • Completed, result not reported2947%
  • Met its primary endpoint1118%
  • Status unknown813%
  • Stopped: other or unclear610%
  • Ongoing58%
  • Missed its primary endpoint23%
  • Stopped: enrollment or feasibility12%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Feb 7, 2023A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regimens for candidemia and/or invasive candidiasis: intravenous…Ibrexafungerp (SCY-078)ScynexisClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 16, 2026RezzayoIn adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and…Mundipharma GmbHApproved
Mar 22, 2023RezzayoIn patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasisMundipharma GmbHApproved
May 10, 2016IbrexafungerpTreatment of invasive Candida infections, including candidemiaGlaxoSmithKline LLCDesignated
Oct 20, 2014Isavuconazonium sulfateTreatment of invasive candidiasis/candidemiaAstellas Pharma Global Development, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.